Bristol-Myers Squibb completed a multi-series note offering via subsidiary CELG-RI, issuing notes maturing 2030–2055. Report dated 2025-11-10.
Bristol-Myers launches $7B cash tender offers to repurchase notes. Key investor implications and context for bondholders. (2025-11-03)
Bristol Myers Squibb announces acquisition of Orbital Therapeutics (Ticker: CELG-RI). Investor-focused summary and analysis — 2025-10-30.
Bristol Myers Squibb Q3 2025 revenue rose 3% to $12.2B and the company raised 2025 guidance. Investor-focused summary and analysis.